• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病心肌病的临床和实验治疗进展:关注当前和未来的治疗策略。

Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy.

机构信息

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.

Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.

出版信息

Front Endocrinol (Lausanne). 2024 Jul 30;15:1451100. doi: 10.3389/fendo.2024.1451100. eCollection 2024.

DOI:10.3389/fendo.2024.1451100
PMID:39140033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11319149/
Abstract

Diabetic cardiomyopathy (DCM) is a severe secondary complication of type 2 diabetes mellitus (T2DM) that is diagnosed as a heart disease occurring in the absence of any previous cardiovascular pathology in diabetic patients. Although it is still lacking an exact definition as it combines aspects of both pathologies - T2DM and heart failure, more evidence comes forward that declares DCM as one complex disease that should be treated separately. It is the ambiguous pathological phenotype, symptoms or biomarkers that makes DCM hard to diagnose and screen for its early onset. This re-view provides an updated look on the novel advances in DCM diagnosis and treatment in the experimental and clinical settings. Management of patients with DCM proposes a challenge by itself and we aim to help navigate and advice clinicians with early screening and pharmacotherapy of DCM.

摘要

糖尿病心肌病(DCM)是 2 型糖尿病(T2DM)的一种严重的继发性并发症,被诊断为在糖尿病患者没有任何先前心血管病史的情况下发生的心脏病。尽管由于它结合了 T2DM 和心力衰竭两种病理学的方面,因此仍然缺乏一个确切的定义,但越来越多的证据表明 DCM 是一种复杂的疾病,应该单独治疗。正是这种模糊的病理表型、症状或生物标志物使得 DCM 难以诊断和早期筛查。这篇综述提供了在实验和临床环境中 DCM 诊断和治疗的新进展的最新观点。DCM 患者的管理本身就是一个挑战,我们旨在帮助临床医生进行早期筛查和 DCM 的药物治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c48/11319149/6d70931b7ed6/fendo-15-1451100-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c48/11319149/dea0ddc942e3/fendo-15-1451100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c48/11319149/6d70931b7ed6/fendo-15-1451100-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c48/11319149/dea0ddc942e3/fendo-15-1451100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c48/11319149/6d70931b7ed6/fendo-15-1451100-g002.jpg

相似文献

1
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy.糖尿病心肌病的临床和实验治疗进展:关注当前和未来的治疗策略。
Front Endocrinol (Lausanne). 2024 Jul 30;15:1451100. doi: 10.3389/fendo.2024.1451100. eCollection 2024.
2
Diabetic cardiomyopathy: Clinical phenotype and practice.糖尿病心肌病:临床表型与实践。
Front Endocrinol (Lausanne). 2022 Dec 7;13:1032268. doi: 10.3389/fendo.2022.1032268. eCollection 2022.
3
Value of circulating miRNA-21 in the diagnosis of subclinical diabetic cardiomyopathy.循环 miRNA-21 在亚临床糖尿病性心肌病诊断中的价值。
Mol Cell Endocrinol. 2020 Dec 1;518:110944. doi: 10.1016/j.mce.2020.110944. Epub 2020 Jul 24.
4
Diabetic cardiomyopathy--fact or fiction?糖尿病性心肌病——确有其事还是子虚乌有?
Herz. 2011 Mar;36(2):102-15. doi: 10.1007/s00059-011-3429-4.
5
Progress in the treatment of diabetic cardiomyopathy, a systematic review.糖尿病心肌病的治疗进展:系统评价。
Pharmacol Res Perspect. 2024 Apr;12(2):e1177. doi: 10.1002/prp2.1177.
6
Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review.细胞外非编码 RNA 在糖尿病心肌病中的生物学功能及临床前景:最新综述
J Cardiovasc Transl Res. 2022 Jun;15(3):469-476. doi: 10.1007/s12265-022-10217-0. Epub 2022 Feb 17.
7
The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.微小 RNA 在糖尿病心肌病的病理生理学、诊断和治疗中的作用。
J Pharm Pharmacol. 2022 Nov 25;74(12):1663-1676. doi: 10.1093/jpp/rgac066.
8
Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy.心力衰竭和糖尿病性心肌病的治疗策略现状。
Biomed Pharmacother. 2022 Jan;145:112463. doi: 10.1016/j.biopha.2021.112463. Epub 2021 Nov 25.
9
Stem cells and diabetic cardiomyopathy: from pathology to therapy.干细胞与糖尿病性心肌病:从病理到治疗
Heart Fail Rev. 2016 Nov;21(6):723-736. doi: 10.1007/s10741-016-9565-4.
10
Diabetic cardiomyopathy: a brief summary on lipid toxicity.糖尿病性心肌病:脂质毒性简述。
ESC Heart Fail. 2023 Apr;10(2):776-790. doi: 10.1002/ehf2.14224. Epub 2022 Nov 11.

引用本文的文献

1
Predicting diabetic cardiomyopathy in type 2 diabetes: development and validation of a nomogram based on clinical and echocardiographic parameters.预测2型糖尿病患者的糖尿病性心肌病:基于临床和超声心动图参数的列线图的开发与验证
Front Endocrinol (Lausanne). 2025 Aug 8;16:1641114. doi: 10.3389/fendo.2025.1641114. eCollection 2025.
2
Deep phenotyping of a modified diabetic cardiomyopathy mouse model which reflects clinical disease progression.一种反映临床疾病进展的改良糖尿病性心肌病小鼠模型的深度表型分析。
Diabetol Metab Syndr. 2025 Aug 14;17(1):334. doi: 10.1186/s13098-025-01913-3.
3
Cardiac structure and function across the continuum of glucose metabolism.

本文引用的文献

1
Early detection of cardiac fibrosis in diabetic mice by targeting myocardiopathy and matrix metalloproteinase 2.通过靶向心肌病变和基质金属蛋白酶 2检测糖尿病小鼠的心脏纤维化
Acta Biomater. 2024 Mar 1;176:367-378. doi: 10.1016/j.actbio.2024.01.017. Epub 2024 Jan 18.
2
Identification of potential biomarkers for diabetic cardiomyopathy using LC-MS-based metabolomics.基于液相色谱-质谱联用代谢组学技术鉴定糖尿病心肌病的潜在生物标志物
Endocr Connect. 2024 Jan 25;13(3). doi: 10.1530/EC-23-0384. Print 2024 Mar 1.
3
Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes.
葡萄糖代谢连续过程中的心脏结构与功能。
Physiol Rep. 2025 Jun;13(12):e70429. doi: 10.14814/phy2.70429.
4
A comprehensive review on diabetic cardiomyopathy (DCM): histological spectrum, diagnosis, pathogenesis, and management with conventional treatments and natural compounds.糖尿病性心肌病(DCM)的全面综述:组织学谱、诊断、发病机制以及传统治疗和天然化合物的管理
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 18. doi: 10.1007/s00210-025-03980-9.
5
Role of Circulating Biomarkers in Diabetic Cardiomyopathy.循环生物标志物在糖尿病心肌病中的作用
Biomedicines. 2024 Sep 23;12(9):2153. doi: 10.3390/biomedicines12092153.
PCSK9 抑制剂对血糖控制和新发糖尿病的影响。
Cardiovasc Diabetol. 2024 Jan 3;23(1):4. doi: 10.1186/s12933-023-02077-y.
4
Circulating thyroid hormones and clinical parameters of heart failure in men.男性循环甲状腺激素与心力衰竭的临床参数。
Sci Rep. 2023 Nov 20;13(1):20319. doi: 10.1038/s41598-023-47391-3.
5
Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models.瞬时受体电位香草酸亚型 1:在糖尿病模型中的心脏保护作用。
Channels (Austin). 2023 Dec;17(1):2281743. doi: 10.1080/19336950.2023.2281743. Epub 2023 Nov 20.
6
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis.针对无动脉粥样硬化性心血管疾病的糖尿病成年人,预测和预防心力衰竭风险的最佳筛查:一项汇总队列分析。
Circulation. 2024 Jan 23;149(4):293-304. doi: 10.1161/CIRCULATIONAHA.123.067530. Epub 2023 Nov 11.
7
A dual-acting aldose reductase inhibitor impedes oxidative and carbonyl stress in tissues of fructose- and streptozotocin-induced rats: comparison with antioxidant stobadine.双重作用的醛糖还原酶抑制剂可抑制果糖和链脲佐菌素诱导的大鼠组织中的氧化应激和羰基应激:与抗氧化剂依布硒啉的比较。
Drug Chem Toxicol. 2024 Sep;47(5):710-720. doi: 10.1080/01480545.2023.2262164. Epub 2023 Oct 5.
8
Oxidative stress signaling in the pathogenesis of diabetic cardiomyopathy and the potential therapeutic role of antioxidant naringenin.氧化应激信号在糖尿病心肌病发病机制中的作用及抗氧化剂柚皮素的潜在治疗作用。
Redox Rep. 2023 Dec;28(1):2246720. doi: 10.1080/13510002.2023.2246720. Epub 2023 Sep 25.
9
Low T3 syndrome predicts more adverse events in patients with hypertrophic cardiomyopathy.低 T3 综合征可预测肥厚型心肌病患者出现更多不良事件。
Clin Cardiol. 2023 Dec;46(12):1569-1577. doi: 10.1002/clc.24156. Epub 2023 Sep 15.
10
Perspectives of circular RNAs in diabetic complications from biological markers to potential therapeutic targets (Review).环状 RNA 在糖尿病并发症中的研究进展:从生物标志物到潜在治疗靶点(综述)。
Mol Med Rep. 2023 Oct;28(4). doi: 10.3892/mmr.2023.13081. Epub 2023 Sep 8.